# US 11,993,612 B2 · LRRK2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,612 B2
- Document ID: US11993612B2
- Status: Granted
- Kind: B2
- Application number: 18/331,289
- Filed: 2023-06-08
- Published: 2023-12-28
- Granted: 2024-05-28
- Earliest claimed: 2021-10-27
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Thomas Jensen; Mikkel Jessing; Wanwan Yu; David Rodriguez Diaz; Jacob Nielsen; Christopher Richard Jones; Thomas Andersen; Mikkel Fog Jacobsen
- Web page: https://patentgrep.com/patent/US11993612B2

## CPC

- C07D 498/22: in which the condensed system contains four or more hetero rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

## Claims

### Claim 1

A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
R1 is R4;
R2 is a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C3-C6 cycloalkyl, or a C1-C3 haloalkyl;
R3 is halogen, cyano, a O-C1-C3 haloalkyl, a C1-C3 haloalkyl, a C3-C6 cycloalkyl, or a C1-C3 alkyl;
R4 is a C3-C6 cycloalkyl;
wherein each cycloalkyl is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of cyano, deuterium, halogen, C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a O-C1-C3 haloalkyl, a O-C1-C3 alkyl, and a C1-C3 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl and a C3-C6 cycloalkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from —CH3, CH2CH3, —CD3 and cyclopropyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is an isotopically labelled C1-C3 alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is —CD3.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is —CH3.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is —CH2CH3.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is unsubstituted.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is substituted with 1 or 2 groups independently selected from the group consisting of cyano, halogen, and a O-C1-C3 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.